SEC Form 4 · accession 0001587221-17-000032
Zosano Pharma Corp · ZSAN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth Greathouse
Director
Period of report
Nov 30, 2017
Accepted (ET)
Dec 4, 2017 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001587221
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 30, 2017 | P | 45,000 | $0.6206 | A | 95,000 | D | |
| Common StockF2 | Dec 1, 2017 | P | 50,000 | $0.6216 | A | 145,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.605 to $0.6304, inclusive. The reporting person undertakes to provide to Zosano Pharma Corporation, any security holder of Zosano Pharma Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
- F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.611 to $0.635, inclusive.